
## Emanuela Martina

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7571206/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Contact allergy to hydrocortisone 21â€acetate in Italy: A <scp>SIDAPA</scp> multicenter study. Contact Dermatitis, 2022, 86, 217-219.	0.8	1
2	The Role of Nutrition in Immune-Mediated, Inflammatory Skin Disease: A Narrative Review. Nutrients, 2022, 14, 591.	1.7	10
3	The Challenge Arising from New Knowledge about Immune and Inflammatory Skin Diseases: Where We Are Today and Where We Are Going. Biomedicines, 2022, 10, 950.	1.4	4
4	Treatment of Moderate to Severe Psoriasis during the COVID-19 Pandemic: Lessons Learned and Opportunities. Journal of Clinical Medicine, 2022, 11, 2422.	1.0	0
5	Patch testing with textile dye mix in Italy: A 2â€year multicenter <scp>SIDAPA</scp> study. Contact Dermatitis, 2021, 84, 265-268.	0.8	3
6	Management of patients with pemphigus vulgaris during the COVIDâ€19 pandemic: Experience of a second level dermatology center. Australasian Journal of Dermatology, 2021, 62, e158-e159.	0.4	4
7	Effects of in vivo application of an overnight patch containing Allium cepa , allantoin, and pentaglycan on hypertrophic scars and keloids: Clinical, videocapillaroscopic, and ultrasonographic study. Dermatologic Therapy, 2021, 34, e14665.	0.8	3
8	Therapeutic Use of Botulinum Neurotoxins in Dermatology: Systematic Review. Toxins, 2021, 13, 120.	1.5	27
9	It is never too late to treat chronic spontaneous urticaria with omalizumab: Realâ€life data from a multicenter observational study focusing on elderly patients. Dermatologic Therapy, 2021, 34, e14841.	0.8	12
10	Vaccination against SARSâ€CoVâ€⊋ and psoriasis: the three things every dermatologist should know. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e428-e430.	1.3	13
11	Patch testing of budesonide in Italy: The <scp>SIDAPA</scp> baseline series experience, 2018–2019. Contact Dermatitis, 2021, 85, 317-323.	0.8	12
12	Saliva Proteomics as Fluid Signature of Inflammatory and Immune-Mediated Skin Diseases. International Journal of Molecular Sciences, 2021, 22, 7018.	1.8	11
13	Vaccines Against SARS-CoV-2 in Psoriasis Patients on Immunosuppressive Therapy: Implications of Vaccination Nationwide Campaign on Clinical Practice in Italy. Dermatology and Therapy, 2021, 11, 1889-1903.	1.4	6
14	How to fight SARS-COV-2 vaccine hesitancy in patients suffering from chronic and immune-mediated skin disease: four general rules. Human Vaccines and Immunotherapeutics, 2021, 17, 4105-4107.	1.4	3
15	Longâ€term efficacy and safety of apremilast in the treatment of plaques psoriasis: A realâ€world, singleâ€center experience. Dermatologic Therapy, 2021, 34, e15179.	0.8	7
16	A tricky case of contact dermatitis: Simultaneous allergic reaction to topical and oral acyclovir, and scar gel. Contact Dermatitis, 2021, 84, 203-205.	0.8	0
17	Time to restart: protocol of resumption of activities of a dermatological clinic of a level II hospital in the COVIDâ€19 era. International Journal of Dermatology, 2020, 59, 1411-1413.	0.5	3
18	Combined treatment of palmar hyperhidrosis with botulinum toxin type A and oxybutynin chloride: Results of a clinical, multicenter, prospective study. Dermatologic Therapy, 2020, 33, e14039.	0.8	12

Emanuela Martina

#	Article	IF	CITATIONS
19	Skin involvement in SARS oVâ€2 infection: Case series. Journal of Medical Virology, 2020, 92, 2332-2334.	2.5	44
20	Global coronavirus pandemic ( SARSâ€CoV â€2): Past , present , and future of pediatric dermatology. Dermatologic Therapy, 2020, 33, e13767.	0.8	3
21	Acne agminata in Crohn's disease: A diagnostic and therapeutic challenge case for dermatologists. Dermatologic Therapy, 2020, 33, e13935.	0.8	2
22	Saliva and Oral Diseases. Journal of Clinical Medicine, 2020, 9, 466.	1.0	45
23	Novel Therapeutic Approaches and Targets for Treatment of Chronic Urticaria: New Insights and Promising Targets for a Challenging Disease. Current Pharmaceutical Biotechnology, 2020, 22, 32-45.	0.9	2
24	Two cases of Hidradenitis suppurativa and botulinum toxin type a therapy: A novel approach for a pathology that is still difficult to manage. Dermatologic Therapy, 2019, 32, e12841.	0.8	19
25	Omalizumab in Chronic Urticaria: An Italian Survey. International Archives of Allergy and Immunology, 2019, 178, 45-49.	0.9	12
26	Predictors of response to omalizumab and relapse in chronic spontaneous urticaria: a study of 470 patients. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 918-924.	1.3	85
27	Botulinum Toxin Off-Label Use in Dermatology: A Review. Skin Appendage Disorders, 2017, 3, 39-56.	0.5	52
28	The effect of low-carbohydrates calorie-restricted diet on visceral adipose tissue and metabolic status in psoriasis patients receiving TNF-alpha inhibitors: results of an open label controlled, prospective, clinical study. Journal of Dermatological Treatment, 2017, 28, 206-212.	1.1	11
29	Hidradenitis suppurativa in Crohn's disease during adalimumab therapy: a paradox?. Acta Dermatovenerologica Alpina, Panonica Et Adriatica, 2016, 26, 21-23.	0.1	8
30	Onabotulinumtoxin type A (Botox®) versus Incobotulinumtoxin type A (Xeomin®) in the treatment of focal idiopathic palmar hyperhidrosis: results of a comparative double-blind clinical trial. Journal of Neural Transmission, 2014, 121, 21-26.	1.4	25
31	Treatment of palmar hyperhidrosis with botulinum toxin type A: results of a pilot study based on a novel injective approach. Archives of Dermatological Research, 2013, 305, 691-697.	1.1	17
32	Adalimumab Modulates Angiogenesis in Psoriatic Skin. European Journal of Inflammation, 2013, 11, 489-498.	0.2	30